Bear Stalking Biotech Sector
The biotech sector saw a significant run-up last month, but for at least one analyst, questions remain about what the second half holds.
Mark Schoenebaum, a biotech analyst with Bear Stearns, cautioned Tuesday that on the basis of his research, he expects the sector's performance to be flat through the end of the year.
According to Schoenebaum, historical trends indicate that "the biotech sector is unlikely to suffer a major correction over the next 3-6 months." But at the same time, the "data also indicate that another significant rally is unlikely this year," Schoenebaum wrote in a research note dated Aug. 1. He believes the sector "could remain range-bound" for the rest of the year.Along with his colleagues, Schoenebaum, whose firm does and seeks to do business with the companies it covers, looked at the seven other instances when the Nasdaq and American Stock Exchange biotech indices were each up 10% or more for a 20-day period. Then they examined the performance of the component companies one month, three months and six months after those rallies. Given his second-half assessment, the analyst recommends that investors dump the "basket approach" to the sector and take a closer look at individual companies' products, pipelines, sales and risks.
Finding FavoritesLooking at the earnings reported in the second quarter, this year's collective upside surprise from the combined results of three big biotechs was the largest it's been since 1999, Schoenebaum says in his research report. Taken together, earnings from Amgen, Genentech and Genzyme were 16.25% more than consensus estimates, compared with 16.08% in the third quarter of 1999.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV